COMMUNIQUÉS West-GlobeNewswire

-
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
23/07/2025 -
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
23/07/2025 -
Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2
23/07/2025 -
Windward Bio Initiates Global Phase 2 Asthma Trial of WIN378, a Potential Best-in-Disease, Long-Acting, Anti-TSLP Monoclonal Antibody
23/07/2025 -
Tenvie Therapeutics Promotes Tony Estrada, PhD, to Chief Executive Officer
23/07/2025 -
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
23/07/2025 -
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
23/07/2025 -
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
23/07/2025 -
Qu Biologics Completes Enrolment of a Unique Study Testing a Novel Immunomodulator to Restore Immune Function in the Elderly
23/07/2025 -
Philips advances minimally invasive therapy procedures in prostate cancer care with FDA 510(k) clearance for image-guided navigation technology
23/07/2025 -
Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock
23/07/2025 -
PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio
23/07/2025 -
AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic Launches
23/07/2025 -
SAFE - Signature d’un avenant n°5 au contrat de financement obligataire en vigueur afin de poursuivre le retournement stratégique de Safe
23/07/2025 -
European Commission approves IMBRUVICA® (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant
23/07/2025 -
European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma
23/07/2025 -
4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock
23/07/2025 -
dacadoo Forges Collaboration with Microsoft to Transform Digital Health Engagement in the Era of AI
23/07/2025 -
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
23/07/2025
Pages